Recorded Presentation from the NCCN 2015 Congress Webinar Series: GU Cancers - Therapeutic Strategies for Advanced Bladder Cancer

Although the standard of care for the treatment of advanced bladder cancer has remained mostly unchanged over the last 30 years, clinical trial data continue to provide insight into potential new therapies. The use of bladder-preserving strategies has improved quality of life, and newer agents that include molecularly targeted therapies and immunotherapies may further improve patient outcomes.

Target Audience

This activity is designed to meet the educational needs of oncologists, nurses, pharmacists, urologists, and other healthcare professionals who manage patients with GU cancers.

Learning Objectives

Following this activity, participants should be able to:

  • Summarize the evaluation of patients with recurrent/persistent disease and factors that determine the management and therapeutic aims for these patients
  • Discuss the types of therapies available in clinical trials for patients with advanced bladder cancer
Additional information
Supporters: 

This activity is supported by an independent educational grant from Astellas and Medivation, Inc.

Supported by educational grants from Bristol-Myers Squibb, Novartis Pharmaceuticals Corporation, and Prometheus Laboratories Inc.

Course summary
Available credit: 
  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.54 ANCC contact hours
  • 0.50 Participation
Course opens: 
12/23/2015
Course expires: 
12/23/2016
Cost:
$0.00

Daniel Petrylak, MD
Yale Cancer Center/Smilow Cancer Hospital

Disclosure of Relevant Financial Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any relevant financial relationships with a commercial interest as defined by the ACCME’s, ANCC’s, and ACPE’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics. Full disclosure of faculty relationships will be made prior to the activity.

The faculty listed below have disclosed the following relevant financial relationships:

Daniel Petrylak, MD
Agenysis, Inc. Grant/Research Support
Bayer HealthCare: Consulting Fees, Honoraria
Bellicum Pharmaceuticals, Inc.: Consulting Fees, Honoraria
Celgene Corporation: Grant/Research Support
Dendreon Corporation: Consulting Fees, Honoraria; Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Consulting Fees, Honoraria
Ferring Pharmaceuticals, Inc. Consulting Fees, Honoraria
Johnson & Johnson Consulting Fees, Honoraria; Grant/Research Support
Medivation, Inc.: Consulting Fees, Honoraria
Millennium Pharmaceuticals, Inc.: Consulting Fees, Honoraria; Grant/Research Support
OncoGenex Pharmaceuticals Inc.: Grant/Research Support
Pfizer Inc.: Consulting Fees, Honoraria
Progenics Pharmaceuticals, Inc: Grant/Research Support
Roche Laboratories, Inc: Consulting Fees, Honoraria; Grant/Research Support
sanofi-aventis U.S.: Consulting Fees, Honoraria; Grant/Research Support
Tyme Inc: Consulting Fees, Honoraria

NCCN Staff Disclosures
The activity planning staff listed below has no relevant financial relationships to disclose:
Ann Gianola, MA; Mark Geisler; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Rose Joyce; Joan S. McClure, MS; Diane McPherson; Deborah Moonan, RN, BSN; Liz Rieder; Shannon K. Ryan; Jennifer McCann Weckesser

The NCCN clinical information team listed below, who have reviewed content, has no relevant financial relationships to disclose:
Mary Dwyer, MS; Rashmi Kumar, PhD

The NCCN clinical information team listed below, who have reviewed content, has the following relevant financial relationships to disclose:

Courtney Smith, PhD
Johnson & Johnson: Equity Interest/Stock Options
Opko Health Inc: Equity Interest/Stock Options

The ACCME/ANCC/ACPE defines “conflict of interest” as when an individual has an opportunity to affect CE content about products or services of a commercial interest with which he/she has a financial relationship.

ACCME, ACPE, and ANCC focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CE activity. ACCME, ACPE, and ANCC have not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME, ACPE, and ANCC defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation to the tasks and methods of delivery.

Physicians
National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

National Comprehensive Cancer Network designates this activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Release date: December 23, 2015
Expiration date: December 23, 2016

Nurses
National Comprehensive Cancer Network (NCCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation. NCCN designates this educational activity for a maximum of 0.54 contact hours. Accreditation as a provider refers to the recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity.

Kristina M. Gregory, RN, MSN, OCN, is our lead nurse planner for this educational activity.

Release date: December 23, 2015
Expiration date: December 23, 2016

Pharmacists

National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Type of Activity: Knowledge 

National Comprehensive Cancer Network designates this continuing education activity for 0.50 contact hour(s) (0.050 CEUs) of continuing education credit in states that recognize ACPE accredited providers.

Universal Activity Number: 0836-0000-15-153-H01-P

Release date: December 23, 2015
Expiration date: December 23, 2016

Available Credit

  • 0.50 ACPE contact hours
  • 0.50 AMA PRA Category 1 Credit™
  • 0.54 ANCC contact hours
  • 0.50 Participation

Accreditation Period

Course opens: 
12/23/2015
Course expires: 
12/23/2016

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
  • Adobe Flash Player and/or an HTML5 capable browser for video or audio playback
  • Adobe Reader or other PDF reader software for certificate viewing/printing